Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification-Reference-Cited by-同舟云学术

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Published:2024-01-09 Issue:1 Volume:79 Page:198-201
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Ursenbach Axel¹,Ruch Yvon²,Hoellinger Baptiste²,Fuchs Anne³,Caspar Stéphanie³,Jegou Frédérick³,Rey David¹,Fafi-Kremer Samira³⁴,Mesplède Thibault⁵,Gantner Pierre³⁴

Affiliation:

1. Le Trait d’Union, HIV-Infection Care Center, Strasbourg University Hospital , Strasbourg , France

2. Infectious Diseases Department, Strasbourg University Hospital , Strasbourg , France

3. Clinical Virology Laboratory, Strasbourg University Hospital , Strasbourg , France

4. INSERM UMR_S1109, Strasbourg University , Strasbourg , France

5. Viroscience Department, Erasmus Medical Center , Rotterdam , The Netherlands

Abstract

Abstract Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae006/56279261/ciae006.pdf

Reference12 articles.

1. ACTG a5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 copies/mL;Taiwo;Clin Infect Dis,2018

2. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection;Cahn;AIDS,2022

3. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression;Revollo;J Antimicrob Chemother,2022

4. Three-year efficacy of switching to dolutegravir plus lamivudine: a real-world study;Palmier;HIV Med,2023

5. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC);Schuurman;J Infect Dis,1995

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With Human Immunodeficiency Virus in Lesotho;Clinical Infectious Diseases;2024-04-03

2. Insights in Dolutegravir-Resistance Pathways;Clinical Infectious Diseases;2024-03-11

3. High-level Dolutegravir Resistance Selection on Dolutegravir/Lamivudine;Clinical Infectious Diseases;2024-03-11